Ocular Therapeutix Inc 2024年度报告

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.⌧Yes◻NoIndicate by check mark if the registrant is not required to file reports pursuant to Section13 or Section15(d) of the Act.◻Yes⌧No Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has beensubject to such filing requirements for the past 90 days.⌧Yes◻No Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).⌧Yes◻No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Acceleratedfiler☐Smallerreportingcompany☐Emerging growth company☐If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying Largeacceleratedfiler☒Non-accelerated filer☐ with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of itsinternal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accountingfirm that prepared or issued its audit report.☒ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrantincluded in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant’s 2025 AnnualMeeting of Stockholders, which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant’sfiscal year ended December 31, 2024. TABLE OF CONTENTS PART I Item1.Business5Item1A.Risk Factors58Item1B.Unresolved Staff Comments104Item1C.Cybersecurity104Item 2.Properties105Item 3.Legal Proceedings105Item 4.Mine Safety Disclosures105PART IIItem 5.Market for Registrant’s Common Equity, Related Stockholder Matters and IssuerPurchases of Equity Securities106Item 6.[Reserved]106Item 7.Management’s Discussion and Analysis of Financial Condition and Results ofOperations107Item7A.Quantitative and Qualitative Disclosures About Market Risk123Item 8.Financial Statements and Supplementary Data124Item 9.Changes in and Disagreements with Accountants on Accounting and FinancialDisclosure124Item9A.Controls and Procedures124Item9B.Other Information125Item9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections125PART IIIItem 10.Directors, Executive Officers and Corporate Governance126Item 11.Executive Compensation126Item 12.Security Ownership of Certain Beneficial Owners and Management and RelatedStockholder Matters126Item 13.Certain Relationships and Related Transactions, and Director Independence127Item 14.Principal Accounting Fees and Services127PART IVItem15.Exhibits and Financial Statement Schedules128Item16.Form 10-K Summary128 FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements that involve substantialrisks and uncertainties. All statements, other than statements of historical facts, contained in thisAnnual Report on Form 10-K, including statements regarding our strategy, future operations, futurefinancial position, future revenues, projected costs, prospects, plans and objectives of management,are forward-looking statements. The words “anticipate”, “believe”, “estimate”, “expect”, “intend”,“designed”, “may”, “might”, “plan”, “predict”, “project”, “target”, “potential”, “goals”, “will”,“would”, “could”, “should”, “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Annual Report on Form 10-K include, among otherthings, statements about: ●our ongoing clinical trials, including our two registrational P